Skip to main content

Recent articles

AACR 2024 – a first look at Astra’s ATM inhibitor

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

AACR 2024 – Transgene gets a “vaccine” boost

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

Familiar targets with a twist

First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.

AACR 2024 – Medicenna looks for a cytokine renaissance

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

AACR 2024 – Vincerx overreaches

The company's comparison of its ADCs to Enhertu seems farfetched.

AACR 2024 – Astra plays up PARP1 inhibition

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.